NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 337

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with Nasdaq’s minimum share price requirement. As a result, every 50 shares of common stock will be consolidated into one, with proportional adjustments made to outstanding equity awards and warrants. No fractional shares will be issued, with cash payments provided instead. The number of authorized shares remains at 300 million, and the split will not impact stockholders’ percentage ownership, aside from adjustments for fractional shares.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

